Entrepreneurship as a process of collective exploration

Clarifies the potentials of the notion of exploration for the analysis of the uncertain and collective nature of entrepreneurship, and provides detailed examination of a case study on a French academic spin-off.entrepreneurship; exploration; opportunity recognition; partnerships

What do business models do? Narratives, calculation and market exploration

Building on a case study of an entrepreneurial venture, we investigate the role played by business models in the innovation process. Rather than debating their accuracy and efficiency, we adopt a pragmatic approach to business models -- we examine them as market devices, focusing on their materiality, use and dynamics. Taking into account the variety of its forms, which range from corporate presentations to business plans, we show that the business model is a narrative and calculative device that allows entrepreneurs to explore a market and plays a performative role by contributing to the construction of the techno-economic network of an innovation.WP abstract: Analyzes the uses and functions of business models through original, qualitative case studies focused on research-based spin-offs.Business models; spin-offs; innovation; commercialization; calculation; exploration; R&D; entrepreneurship

Que vaut une molécule ? L'utilisation de la formule des flux de trésorerie actualisés dans les projets de développement de nouveaux médicaments

http://f.hypotheses.org/wp-content/blogs.dir/659/files/2012/06/Doganova_Texte_AFS2013.pdfNational audienc

Entrepreneurship as a process of collective exploration

http://www.csi.ensmp.fr/Items/WorkingPapers/Download/DLWP.php?wp=WP_CSI_017.pdfClarifies the potentials of the notion of exploration for the analysis of the uncertain and collective nature of entrepreneurship, and provides detailed examination of a case study on a French academic spin-off

Controversial valuations. Assembling environmental concerns and economic worth in clean-tech markets

International audienceEnvironmental concerns are increasingly seen a not only raising a threat to which firms need to adapt by becoming "greener" and more "socially esponsible", but also as offering opportunities or new business development. Instead of being relinquished to the status of externalities, which firms more or less willingly come to internalize, environmental qualities (or deficiencies) now sometimes happen to be brought to he enter of the calculation of the value of new products. The emergence of a "clean tech" sector epitomizes this move towards the economization (Callon and Caliskan 2009) of concerns which have hitherto been considered as lying outside of the market. This paper proposes to investigate the construction of clean tech markets by examining the mechanisms through which new technologies succeed (or fail) to be transformed into goods which possess a twofold value: environmental quality (their "cleanliness") and economic worth (their price)

Making rareness count: testing and pricing orphan drugs

This paper examines the testing and the pricing of orphan drugs, e.g. drugs for patients suffering from rare diseases. Due to the small size of these populations, orphan molecules question established evidentiary practices, namely randomized controlled trials (RCT) and health technology assessments (HTA), driven by numbers and statistical reasoning. Drawing on the notions of “statactivism” (Bruno et al. 2014) and “evidence-based activism” (Rabeharisoa et al. 2014), this paper shows how stakeholders in the field of rare diseases come to test a variety of solutions, ranging from adapting RCT and HTA on the fringe, advocating for exceptional procedures, to recomposing RCT and HTA from within. These initiatives offer new insights into the pricing of orphan drugs as a testing device of who is accountable for the evaluation of these molecules, and of how rare diseases are made to count for society at large

What do business models do? Narratives, calculation and market exploration

http://www.csi.ensmp.fr/Items/WorkingPapers/Download/DLWP.php?wp=WP_CSI_012.pdfCSI WORKING PAPERS SERIES 012International audienceBuilding on a case study of an entrepreneurial venture, we investigate the role played by business models in the innovation process. Rather than debating their accuracy and efficiency, we adopt a pragmatic approach to business models -- we examine them as market devices, focusing on their materiality, use and dynamics. Taking into account the variety of its forms, which range from corporate presentations to business plans, we show that the business model is a narrative and calculative device that allows entrepreneurs to explore a market and plays a performative role by contributing to the construction of the techno-economic network of an innovation.WP abstract: Analyzes the uses and functions of business models through original, qualitative case studies focused on research-based spin-offs.Analyse des usages et fonctions des "business models" à partir d'études de cas originaux dans le domaine des entreprises innovantes issues de la recherche

Conflits de valorisation et fabrique du territoire. Tensions autour des ressources naturelles dans la forêt tropicale guyanaise

editorial reviewe

Business model innovation and owner-managers: the moderating role of competition

This study examines the relationship between owner–managers, business model innovation and competition. We present a newly constructed data set of 111 new firms that launched electronic trading platforms (business model innovations) in the US and European bond markets between 1995 and 2004. We contribute to the emerging literature on business model innovation by integrating effectuation theory with the Austrian school’s view of competition as a discovery process to examine the role of the entrepreneur in business model design. Our findings reveal that the presence of entrepreneurs as owner–managers positively influences the degree of innovation: this relation is stronger in less competitive environments but is weaker (and may even reverse) in highly competitive environments. We discuss implications for theory and for entrepreneurs in influencing the degree of business model innovation, and suggest future directions for research.This is the author accepted manuscript. The final version is available from Wiley via http://dx.doi.org/10.1111/radm.1209

Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases

Rare diseases are associated with difficulties in addressing unmet medical needs, lack of access to treatment, high prices, evidentiary mismatch, equity, etc. While challenges facing the development of drugs for rare diseases are experienced differently globally (i.e., higher vs. lower and middle income countries), many are also expressed transnationally, which suggests systemic issues. Pharmaceutical innovation is highly regulated and institutionalized, leading to firmly established innovation pathways. While deviating from these innovation pathways is difficult, we take the position that doing so is of critical importance. The reason is that the current model of pharmaceutical innovation alone will not deliver the quantity of products needed to address the unmet needs faced by rare disease patients, nor at a price point that is sustainable for healthcare systems. In light of the problems in rare diseases, we hold that re-thinking innovation is crucial and more room should be provided for alternative innovation pathways. We already observe a significant number and variety of new types of initiatives in the rare diseases field that propose or use alternative pharmaceutical innovation pathways which have in common that they involve a diverse set of societal stakeholders, explicitly address a higher societal goal, or both. Our position is that principles of social innovation can be drawn on in the framing and articulation of such alternative pathways, which we term here social pharmaceutical innovation (SPIN), and that it should be given more room for development. As an interdisciplinary research team in the social sciences, public health and law, the cases of SPIN we investigate are spread transnationally, and include higher income as well as middle income countries. We do this to develop a better understanding of the social pharmaceutical innovation field’s breadth and to advance changes ranging from the bedside to system levels. We seek collaborations with those working in such projects (e.g., patients and patient organisations, researchers in rare diseases, industry, and policy makers). We aim to add comparative and evaluative value to social pharmaceutical innovation, and we seek to ignite further interest in these initiatives, thereby actively contributing to them as a part of our work